Primer: Actinium Pharmaceuticals (ATNM US) - Aug 2026
Actinium's lead candidate, Iomab-B, faced a significant setback in August 2024 when the FDA determined the Phase 3 SIERRA trial data was...
91 Views
No more insights
𝛼SK or SearchENTITY
Actinium Pharmaceuticals (ATNM US)
Actinium Pharmaceuticals (ATNM US)
3
Analysis
Health Care • United States
Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops pipeline of antibody radiation conjugates for targeted conditioning and combination therapies. Actinium Pharmaceuticals serves clients in the United States.
morex